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Abstract
Research on African Staphylococcus aureus has been largely neglected in the past, despite the cultural and geographical diversity in Africa,
which has a signiﬁcant impact on the epidemiology of this pathogen. The polarity between developed urban societies and remote rural
populations (e.g. Pygmies), combined with close contact with animals (e.g. livestock and domestic animals, and wildlife), makes the
epidemiology of S. aureus on the African continent unique and fascinating. Here, we try to draw an epidemiological picture of S. aureus
colonization and infection in Africa, and focus on the wide spread of Panton–Valentine leukocidin-positive isolates, the emergence of the
hypervirulent methicillin-resistant S. aureus (MRSA) clone USA300, and the dissemination of the typical African clone MRSA sequence
type 88.
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Introduction
Africa is a prosperous continent. Despite the uneven distri-
bution of wealth, the lack of translation of economic growth to
productive jobs, and poor governance structures in some
countries, we are facing a continent with the higher birth rates
and rates of economic growth in some countries than in the
rest of the world [1,2]. However, the links to global markets,
particularly the shipment of goods and passenger trafﬁc, are
still loose; therefore, interest in the dissemination of emerging
pandemic pathogens might have been low in Africa. For
instance, the picture of the spread of community-acquired
methicillin-resistant Staphylococcus aureus (MRSA) in Africa is
unclear, in contrast to the rest of the world [3]. To date,
research in infectious diseases in Africa has been focused on
the ‘big three’ (malaria, human immunodeﬁciency virus (HIV)/
AIDS, and tuberculosis), but is now being expanded to
‘neglected tropical diseases’ as promoted by the Millennium
Development Goals [4,5]. However, major bacterial pathogens
are not yet sufﬁciently considered in future research
agendas, although the burden of infection by, for instance,
S. aureus, Streptococcus pneumoniae or extended-spectrum
b-lactamase-producing Enterobacteriaceae is high in Africa [5].
This is urgently needed, as HIV/AIDS, malaria, malnutrition,
crowded living conditions, high temperatures and humidity
increase the risk of other bacterial infections [6,7].
Research on bacterial infections in Africa should enter a
phase where the focus of our attention is not limited to the
high burden of disease and medical need. Phylogenetic analyses
might also help us to understand the origin of major pathogens,
considering Africa as the ‘cradle of man’ [8]. Indeed, the spread
of some pathogens is linked to human migration, suggesting
Africa as the origin of a number of bacteria, such as
Helicobacter pylori [9], Mycobacterium tuberculosis complex
[10], Mycobacterium leprae [11], and Salmonella enterica Typhi
[12]. This might also apply to S. aureus [13].
The objective of this review is to report the epidemiology of
S. aureus colonization and infection in Africa, considering the
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geographical and lifestyle differences between North Africa
and sub-Saharan Africa. We also point out the challenges in
combating S. aureus-related infections.
Epidemiology of S. aureus Colonization
S. aureus colonization is a risk factor for subsequent infection
caused by the colonizing clone [14,15]. Therefore, knowledge
about colonizing isolates is key to understanding S. aureus
infection. The colonization pattern in different age groups is
similar in Africa and Europe, with high colonization rates
immediately after birth and in teenagers (Fig. 1) [16]. This
holds true not only for urban and semi-urban populations, but
also for remote Pygmy populations [13].
Conﬁrmed risk factors for S. aureus colonization in Africa
are HIV infection [17,18], frequent hand-washing (more than
three times daily) [19], living in rural areas, and being
hospitalized on surgery wards [20]. A risk factor for S. aureus
colonization in infancy is S. aureus colonization of the mother
[21]. In contrast, age of <5 years, higher educational level of
parents [19] and male sex [22] seem to be protective against
S. aureus colonization.
As in other parts of the world, S. aureus also colonizes
animals, such as pets (e.g. dogs), livestock (e.g. donkeys, pigs,
and sheep) or wild animals (e.g. monkeys, chimpanzees,
gorillas, and bats) [23–29]. The zoonotic risk for humans has
not yet been sufﬁciently studied, but might be lower than that
associated with the emerging burden of livestock-associated
MRSA in some parts of Europe [30–32]. So far, only MRSA
colonization in pigs (12.5% in South Africa and 1.3% in Senegal)
might point towards future problems. However, colonization
rates are still lower than porcine colonization rates in Belgium
(40%), Germany (43.5%), and Spain (46.0%) [26,33,34]. Only
isolates belonging to sequence type (ST)5-MRSA-IV and
ST88-MRSA-IV, and not ST398-MRSA, have so far been found
in African livestock [26].
Not only livestock but also wild animals, such as chimpan-
zees and gorillas, can be affected by human-associated S. aureus
lineages, causing both asymptomatic colonization [35] and fatal
infection [36]. This represents ia high risk for endangered
species such as the great apes [35]. It is noteworthy that
monkeys can be colonized with a highly divergent S. aureus
subclade comprising isolates belonging to multilocus sequence
types ST1874, ST2058, and ST2071, and others, showing
almost no antibiotic resistance [24]. One isolate belonging to
this divergent clade has so far been found only once in humans,
in Gabon [24]. Transmission of this highly divergent subclade
between animals and humans is therefore possible, but seems
to be rare.
The spectrum of S. aureus-related infections differs from
that in other parts of the world, with a higher proportion of
pyomyositis, of up to 27%, among cases with bone, skin and
soft tissue infection [37], and up to 21.7% among all
S. aureus-related infections [38]. Multifocal lesions are fre-
quently encountered, and occur mostly in immunocompro-
mised patients, but might also affect immunocompetent
individuals [39,40]. In addition, some studies have suggested
a higher proportion of S. aureus in urinary tract infections: 6.3–
13.9% of urinary tract infections are caused by S. aureus in
Senegal [41], Ghana [42], and Nigeria [43], as compared with
1.06% in Europe and Brazil [44]. In general, S. aureus is a major
pathogen in bloodstream infections (9.5–39.0%), skin and soft
tissue infections (62.8–90.0%), ear, nose and throat infections
(16.7–29.0%), and surgical site infections (20.4–32.0%) [45–50].
A few prospective studies have revealed a higher incidence
of S. aureus infection in Africa than in industrialized countries.
The annual incidence of S. aureus bacteraemia was 3.28 cases
per 1000 hospital admissions (South Africa) or between 101
and 178 cases per 100 000 child-years (Mozambique), with the
highest incidence in children aged <5 years [51,52]. For
comparison, the annual incidence rates of community-acquired
S. aureus bloodstream infection in the USA were 2.3 cases per
100 000 person-years for methicillin-sensitive S. aureus
(MSSA) and 1.5 cases per 100 000 person-years for MRSA
[53].
Annual incidence rates were high for skin and soft tissue
infections (1572 cases per 100 000 children aged <12 months)
and mastitis (452 cases per 100 000 mothers), as a study from
Gabon revealed [21].
FIG. 1. Staphylococcus aureus nasal colonization rates in Africa.
Community-associated S. aureus nasal carrier studies (1985–2013)
performed in Africa are included in this diagram [13,17,18,20–
22,26,88–95]. The trend-line was ﬁtted by use of a polynomial
regression (order 4).
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Detailed molecular characterization of clinical S. aureus
isolates from Africa has been largely neglected in the past.
Only cases of S. aureus-related infections in travellers return-
ing from Africa have suggested that African S. aureus might
have a different genetic background and might be more
virulent than isolates from Europe. Reports of fatal S. aureus
pneumonia and complicated skin and soft tissue infection in
travellers returning from Africa were frequently associated
with isolates producing Panton–Valentine leukocidin (PVL)
[54–57]. PVL can lyse granulocytes, and is associated with skin
and soft tissue infection [58,59]. Field studies performed in
Africa in the last two decades have showed PVL-positive
S. aureus infection in travellers: Africa is now considered to be
a PVL-endemic region with high rates of PVL-positive isolates,
mainly MSSA, ranging from 17% to 74% [38]. This is in stark
contrast to Europe, where the prevalence of PVL-positive
isolates is low (0.9–1.4%) [60]. Studies from Gabon and South
Africa further support the association of PVL with abscesses
and skin and soft tissue infection [61,62]. The reasons for the
high prevalence of PVL are unknown, but might be related to
the host (i.e. altered C5a receptors, which have been identiﬁed
as PVL targets), so far unidentiﬁed virulence factors of
S. aureus that facilitate dissemination (similarly to sasX), and
the humid environment of tropical Africa [6,63,64].
Antimicrobial Resistance
As in other parts of the world, antimicrobial resistance is
emerging in S. aureus in Africa, particularly methicillin resis-
tance. We refer here to the recent meta-analysis on MRSA in
Africa by Falagas et al. [65] for more detailed information. One
striking feature of African MSSA in urban areas is the high level
of resistance to penicillin (73.7–100%) [66,67], co-trimoxazole
(15–89.1%) [50,68], and tetracycline (21.8–92%) [69,70]. It is
noteworthy that this is in contrast to isolates from individuals
from remote regions, such as Pygmies, where resistance to
penicillin (35.3%), co-trimoxazole (11.8%) and tetracycline
(5.8%) was clearly lower [13]. There seems to be a tendency
for there to be higher rates of resistance to fusidic acid in
North Africa (13–62%) than in sub-Saharan Africa (0–2%)
[67,69,71–73]. Data on the prescription and use of
antibiotics are scarce for urban populations and absent for
remote populations. The most frequently prescribed anti-
biotics in urban settings (percentage of encounters) were
co-trimoxazole (40%), amoxycillin (11.8%) and metronidazole
(8.6%) in Gambian children aged <5 years [74]. This is in line
with a study from Gabon, where the proportion of pre-
sampling antibiotic treatment was high for ampicillin–
amoxycillin (37.6%) and co-trimoxazole (3.0%) [46]. The
frequent prescription of (amino)penicillins and co-trimoxazole
could explain the high rates of resistance to these antimicrobial
agents in sub-Sahara Africa.
Although MRSA rates are usually <50% among S. aureus
isolates, the emergence of borderline oxacillin-resistant
S. aureus (BORSA) and glycopeptide-intermediate S. aureus
(GISA) in Africa could become problematic. The proportion of
BORSA among S. aureus in Tunisia was 1.2%, and isolates were
genetically unrelated, suggesting wider dissemination of
BORSA in the S. aureus population [75]. In Tunisia in 2008, a
GISA strain was isolated from a woman suffering from
pemphigus. The isolate was MRSA, showed a glycopeptide
MIC of 16 mg/L, and belonged to ST247 (SCCmec I, t052)
[76]. The ﬁrst GISA isolate in South Africa was reported in
2000 [77].
Population Structure
The distribution of major African MSSA clones is heteroge-
neous. ST5-MSSA and ST15-MSSA are highly prevalent in West
Africa (including Cameroon). Isolates belonging to ST5 rarely
encode PVL; however, the proportion of PVL-positive isolates
in this lineage can be up to 33% [38,78]. ST15 isolates
frequently harbour PVL (25.9–90%) and enterotoxin A (22–
74.6%) [21,38,69]. ST8-MSSA isolates are mainly found in the
Maghreb, including Nigeria, and only rarely carry the
PVL-encoding genes (up to 9% in Morocco) [38].
In Central and West Africa, S. aureus isolates mainly
belong to ST30, ST121, and ST152 (Fig. 2). These are the
major PVL-positive clones, with high proportions of PVL-
positive isolates in ST30 (9.1–100%), ST121 (50–93%), and
ST152 (97–100%) [21,22,26,38]. A similar genetic background
of MSSA and MRSA among the major clones is evident for
ST5 and ST8 (Figs 2 and 3). Whereas ST5-MRSA and
ST5-MSSA are highly prevalent in the same geographical
region (Central and West Africa), ST8-MRSA (Central and
South Africa) and ST8-MSSA (Maghreb) clearly differ in their
geographical distribution (Figs 2 and 3). This might suggest
that African ST5-MRSA evolved in Africa from ST5-MSSA
through acquisition of the SCCmec element, whereas this
might not be true for ST8-MRSA. It is noteworthy that some
ST8-MRSA isolates that are closely related to the hypervir-
ulent CA-MRSA clone USA300 (ST8, t008, PVL-positive, and
arginine catabolic mobile element [ACME]-positive) were
recently reported from Gabon and Ghana (ST8, t121 and
t112, PVL-positive, and ACME-positive) [21,72]. There is one
reported case of a severe invasive infection by this
USA300-related clone, causing bacteraemia, pneumonia and
pericarditis in an otherwise healthy person in Gabon [79].
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ST80-MRSA-IV is mainly found in the Maghreb, and
frequently carries PVL (91.7–100%) [70,80]. Whereas
ST80-MRSA-IV from Egypt did not show any resistance to
tetracycline and fusidic acid [81], this resistance was detected
in isolates from Algeria (tetracycline, c. 75%) and Tunisia
(tetracycline, 4.7%; fusidic acid (intermediate), 3.1%) [80].
ST80-MRSA-IV is the major community-acquired MRSA clone
in Europe that is always PVL-positive and usually resistant to
tetracycline and intermediately resistant to fusidic acid [82].
The geographical proximity, the phylogenetic relatedness and
the ﬁrst report of the clone in North Africa in 2006 [82]
suggest that this MRSA clone spread from Europe to the
Maghreb. However, whole genome analyses are warranted to
assess this hypothesis.
ST88-MRSA is predominant in West, Central and East
Africa (Fig. 2), where the prevalence of PVL and other
virulence factors is very low [61,66,78,82]. This clone has
been only sporadically reported around the globe, except for
the Far East, where the prevalence rates among MRSA isolates
are 5.3–10% (China) and 12.5% (Japan) [83–85]. This propor-
tion is markedly lower than that Africa, where ST-88-MRSA
accounts for 24.2–83.3% of all MRSA isolates [61,86]. As the
FIG. 2. Distribution of methicillin-
sensitive Staphylococcus aureus (MSSA)
clones in Africa. The three major MSSA
multilocus sequence types (STs) of each
study were identiﬁed [13,21,22,26,38,
50,61,62,66,69,72,78,96–100]. Of these,
the six most widely distributed clones in
Africa are shown. Sporadic clones are
indicated by letters. STs from Uganda and
Tunisia were derived from spa types.
FIG. 3. Distribution of methicillin-
resistant Staphylococcus aureus (MRSA)
clones in Africa. The three major MRSA
multilocus sequence types (STs) of each
study were identiﬁed [21,22,50,61,62,66–
70,72,78,81,86,96,98–102,102–107]. Of
these, the ﬁve most widely distributed
clones in Africa are shown. Sporadic
clones are indicated by letters. STs from
Uganda were derived from spa types.
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origin of this clone is unclear, we suggest naming
ST88-MRSA-III/IV the ‘African clone’.
ST239/241-MRSA-I/III/IV is prevalent on the whole African
continent, and this is mirrored by the global spread of this
Iberian–Hungarian–Brazilian clone (Fig. 2).
Conclusions
As in other parts of the world, there is wide diversity among
S. aureus lineages colonizing and infecting the African popu-
lation, in part with different genetic backgrounds. In partic-
ular, one MRSA clone seems to be a typical African clone
(ST88-MRSA-III/IV) that is—except for Far East Asia—only
sporadically reported around the world. ST80-MRSA-IV is
widely disseminated in the Maghreb, but is rarely found in
sub-Saharan Africa. African S. aureus isolates are character-
ized by a high proportion of resistance to penicillin, tetracy-
cline, and co-trimoxazole, which mirrors the frequent
prescription of these drugs. An exceptionally large number
of MSSA isolates harbour PVL; thus, Africa has been
considered to be an endemic region for PVL-positive
S. aureus. The reasons for this high prevalence are unknown,
but might be related to altered interplay of the host, the
microorganism, and the environment. As implemented in
Europe, the establishment of multi-country networks for the
surveillance of S. aureus infections and characterization of
strains will further enhance our understanding of the pecu-
liarities of the epidemiology and contribution of African
strains to global S. aureus infections and spread [5,87]. In
future, special emphasis should be put on studies of the
epidemiology of S. aureus in this part of the world, as the
medical burden caused by this pathogen must not be further
neglected.
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